Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers / Kelly, Cm; Krishnamurthy, S; Bianchini, G; Litton, Jk; Gonzalez-Angulo, Am; Hortobagyi, Gn; Pusztai, L. - In: CANCER. - ISSN 0008-543X. - (2010).